LAVA Therapeutics N.V. Ordinary Shares(LVTX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$1.74
52-Week Range
$1.27 – $1.82
IV Rank (30D)
46.34
Straddle Price
$0.00
P/C Vol Ratio
169.00
Market Cap
$0.0B
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$0.0B

LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan -1.70% 4
Feb +6.43% 4
Mar -5.74% 5
Apr -9.46% 5
May -2.62% 5
Jun -7.67% 5
Jul -5.53% 5
Aug -2.83% 5
Sep +9.69% 5
Oct +8.30% 5
Nov +8.62% 5
Dec -29.32% 4
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $1.65
SMA 50: $1.59
SMA 200: $1.39
Current: $1.74
EMA 12: $1.69
EMA 26: $1.64
MACD: 0.0450 | Signal: 0.0149
BULLISH
ADX (14): 23.88
WEAK TREND
+DI: 26.02
−DI: 19.82
Momentum Oscillators
RSI (14): 62.23
NEUTRAL
Stoch %K: 80.26
Stoch %D: 76.62
Williams %R: -34.72
Volume & Volatility
BB Upper: $1.77
BB Lower: $1.53
NEUTRAL
OBV: 97,698,779
Vol SMA 20: 131,735
Vol ROC: 645.64%
ATR: $0.07
True Range: $0.20
HV 20: 38.9%
HV 30: 45.0%
HV 60: 36.7%

Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:16.651000
Date Range: 2023-11-24T00:00:00 – 2025-11-20T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
1 of 1 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-03-28 Pre-Market 270.66% 7.44% 0.03x Within
Options Activity
IV Rank (30D)
46.34
IV Rank (7D)
46.34
Avg IV
712.2%
Straddle (30D)
$0.00
Straddle (7D)
$0.00
P/C Volume
169.00
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
-0.12
Correlation (SPY)
-3.5%
0.00
Ann. Volatility
38.9%
SPY Volatility
11.1%

Negative beta - stock moves opposite to market

Beta & Alpha Over Time
Institutional Ownership (13F)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

# Filer Shares Value % of Total % of Float Period
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
Insider Activity
Latest: 2025-11-17
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-11-17 KAREN J WILSON Director Disp (D) −10,000 EDGAR
2025-11-17 Mary E. Wadlinger Director Disp (D) −33,390 opt EDGAR
2025-11-17 Kapil Dhingra Director Disp (D) −30,000 EDGAR
2025-11-17 James Noble Director Disp (D) −33,390 opt EDGAR
2025-11-17 Jay T. Backstrom Director Disp (D) −33,390 opt EDGAR
2025-11-17 Peter A Kiener Director Disp (D) −33,390 opt EDGAR
2025-11-17 Christy J. Oliger Director Disp (D) −33,390 opt EDGAR
2025-11-17 Fred M Powell Chief Financial Officer Disp (D) −65,000 EDGAR
2025-11-17 STEPHEN A HURLY Chief Executive Officer Disp (D) −5,000 EDGAR
2025-10-20 Gilde Healthcare IV U.A. Cooperatieve 10%+ Owner Sell (S) −5,742,740 $1.47 -$8.45M EDGAR
2025-10-15 Gilde Healthcare IV U.A. Cooperatieve 10%+ Owner Sell (S) −950,054 $1.51 -$1.44M EDGAR
2025-10-10 Gilde Healthcare Holding B.V. 10%+ Owner Sell (S) −253,984 $1.56 -$395.8K EDGAR
2025-09-23 Versant Ventures VI GP, L.P. 10%+ Owner Sell (S) −17,420,418 $1.40 -$24.41M EDGAR
2025-09-18 Versant Vantage I, L.P. 10%+ Owner Sell (S) −10,106,604 $1.49 -$15.01M EDGAR
2025-02-18 Christy J. Oliger Director Grant (A) +33,390 RSU EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
3 insiders · @ $1.74
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Gilde Healthcare Holding B.V. 10%+ Owner 5,294,178 $9.21M -$395.8K 1 2025-10-10
2 Gilde Healthcare IV U.A. Cooperatieve 10%+ Owner 4,128,912 $7.18M -$9.89M 2 2025-10-20
3 Versant Vantage I, L.P. 10%+ Owner 3,358,920 $5.84M -$15.01M 1 2025-09-18
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

TTM Revenue$0.0B
TTM Net Income$-0.0B
TTM EPS$-0.87